T1	PROC 60 80	terapia inmunológica
T2	CHEM 257 267	BMS-986253
#1	AnnotatorNotes T2	C4688407; BMS-986253; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 102 122	fármaco experimental
#2	AnnotatorNotes T3	C0304229; Experimental drug; Pharmacologic Substance
T4	CHEM 167 176	Nivolumab
#3	AnnotatorNotes T4	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	DISO 194 202	cánceres
#4	AnnotatorNotes T5	C0006826; Malignant Neoplasms; Neoplastic Process
T6	PROC 236 253	Estudio fase 1/2a
T7	CHEM 287 296	nivolumab
#5	AnnotatorNotes T7	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T8	DISO 300 308	cánceres
#6	AnnotatorNotes T8	C0006826; Malignant Neoplasms; Neoplastic Process
T9	DISO 342 350	Cánceres
#7	AnnotatorNotes T9	C0006826; Malignant Neoplasms; Neoplastic Process
T10	DISO 432 444	tumor sólido
#8	AnnotatorNotes T10	C0280100; Solid Neoplasm; Neoplastic Process
T11	DISO 512 530	enfermedad medible
#9	AnnotatorNotes T11	C1513041; Measurable Disease; Disease or Syndrome
T12	DISO 561 567	lesión
#10	AnnotatorNotes T12	C0221198; Lesion; Finding
T13	PROC 583 590	biopsia
#11	AnnotatorNotes T13	C0005558; Biopsy; Diagnostic Procedure
T14	DISO 706 752	tumores primarios del sistema nervioso central
T15	ANAT 728 752	sistema nervioso central
#12	AnnotatorNotes T15	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T16	ANAT 754 757	SNC
#13	AnnotatorNotes T16	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T17	DISO 803 813	enfermedad
#14	AnnotatorNotes T17	C0012634; Disease; Disease or Syndrome
T18	DISO 853 874	metástasis cerebrales
#15	AnnotatorNotes T18	C0220650; Metastatic malignant neoplasm to brain; Neoplastic Process | C0555278; Cerebral metastasis; Neoplastic Process
T19	DISO 932 953	enfermedad autoinmune
#16	AnnotatorNotes T19	C0004364; Autoimmune Diseases; Disease or Syndrome
T20	DISO 1004 1014	afecciones
#17	AnnotatorNotes T20	C0221423; Illness (finding); Sign or Symptom
T21	PROC 1029 1071	tratamiento sistémico con corticosteroides
T22	CHEM 1055 1071	corticosteroides
#18	AnnotatorNotes T22	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T23	CHEM 1097 1107	prednisona
#19	AnnotatorNotes T23	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T24	CHEM 1117 1146	medicamentos inmunosupresores
T25	DISO 1357 1396	Síndrome de Inmunodeficiencia Adquirida
#20	AnnotatorNotes T25	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T26	DISO 1398 1402	SIDA
#21	AnnotatorNotes T26	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T27	CHEM 1406 1425	Agentes citotóxicos
#22	AnnotatorNotes T27	C0304497; Cytotoxic agent; Pharmacologic Substance
T28	PROC 1502 1525	terapia anticancerígena
T29	PROC 1548 1555	terapia
#23	AnnotatorNotes T29	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T30	CHEM 123 133	BMS-986253
#24	AnnotatorNotes T30	C4688407; BMS-986253; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T31	DISO 464 475	metastásico
#25	AnnotatorNotes T31	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T32	DISO 765 783	metástasis del SNC
T33	ANAT 780 783	SNC
#26	AnnotatorNotes T33	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T34	ANAT 864 874	cerebrales
#27	AnnotatorNotes T34	C0242202; Cerebrum; Body Part, Organ, or Organ Component | C1269537; Entire brain; Body Part, Organ, or Organ Component | C1280654; Entire cerebrum; Body Part, Organ, or Organ Component
T35	PROC 1186 1216	administración del tratamiento
T36	PROC 1274 1281	pruebas
#28	AnnotatorNotes T36	C1510438; Assay; Laboratory Procedure
T37	DISO 1300 1336	Virus de la Inmunodeficiencia Humana
T38	DISO 1338 1341	VIH
#29	AnnotatorNotes T38	C0458074; Human immunodeficiency virus (HIV) status; Finding
T39	Date 13 17	2018
T40	LIVB 180 189	pacientes
#30	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T42	Spec_cue 973 983	sospechada
T43	Dose 1073 1080	> 10 mg
T44	Duration 1157 1168	los 14 días
T48	Duration 1458 1476	al menos 4 semanas
T49	CONC 1486 1498	última dosis
T41	LIVB 688 701	Participantes
#31	AnnotatorNotes T41	C4554048; Study Participant; Population Group
T50	LIVB 914 927	Participantes
#32	AnnotatorNotes T50	C4554048; Study Participant; Population Group
T51	LIVB 986 999	Participantes
#33	AnnotatorNotes T51	C4554048; Study Participant; Population Group
T52	LIVB 1231 1244	Participantes
#34	AnnotatorNotes T52	C4554048; Study Participant; Population Group
T53	LIVB 835 848	participantes
#35	AnnotatorNotes T53	C4554048; Study Participant; Population Group
T45	PROC 388 425	Confirmación histológica o citológica
#36	AnnotatorNotes T45	C1305671; Cytology procedure; Laboratory Procedure + C0344441; Histology Procedure; Laboratory Procedure
T46	PROC 898 908	reclutados
#37	AnnotatorNotes T46	C0242800; Patient Recruitment; Research Activity
A1	Assertion T19 Speculated
A3	Status T19 History_of
A4	Status T37 History_of
A5	Status T38 History_of
A6	Status T25 History_of
A7	Status T26 History_of
A8	Status T28 History_of
#38	AnnotatorNotes T1	C0021083; Immunotherapy; Therapeutic or Preventive Procedure
#39	AnnotatorNotes T32	C0686377; CNS metastases; Neoplastic Process
#40	AnnotatorNotes T24	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
#41	AnnotatorNotes T37	C0458074; Human immunodeficiency virus (HIV) status; Finding
#42	AnnotatorNotes T28	C0920425; cancer treatment; Therapeutic or Preventive Procedure 
T47	Neg_cue 494 496	no
T54	Quantifier_or_Qualifier 497 506	resecable
A2	Assertion T54 Negated
#43	AnnotatorNotes T54	C1514888; Resectable; Qualitative Concept
R1	Used_for Arg1:T3 Arg2:T1	
R2	Used_for Arg1:T30 Arg2:T1	
R3	Combined_with Arg1:T30 Arg2:T4	
R4	Combined_with Arg1:T3 Arg2:T4	
R5	Experiences Arg1:T40 Arg2:T1	
R6	Experiences Arg1:T40 Arg2:T3	
R7	Experiences Arg1:T40 Arg2:T5	
R8	Combined_with Arg1:T2 Arg2:T7	
T55	Quantifier_or_Qualifier 203 212	avanzados
#44	AnnotatorNotes T55	C0205179; Advancd phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R9	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T55	
T56	Quantifier_or_Qualifier 309 318	avanzados
#45	AnnotatorNotes T56	C0205179; Advancd phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R10	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T56	
T57	Quantifier_or_Qualifier 351 360	avanzados
#46	AnnotatorNotes T57	C0205179; Advancd phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R11	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T57	
T58	Quantifier_or_Qualifier 454 462	avanzado
#47	AnnotatorNotes T58	C0205179; Advancd phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R12	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T58	
R13	Before Arg1:T10 Arg2:T31	
R14	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T54	
R15	Negation Arg1:T47 Arg2:T54	
T59	Observation 477 487	recurrente
#48	AnnotatorNotes T59	C0679254; Disease recurrence; Finding
R16	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T59	
T60	CONC 535 546	RECIST v1.1
#49	AnnotatorNotes T60	C4086827; Response Evaluation Criteria in Solid Tumors Version 1.1; Intellectual Product)
T61	Result_or_Value 608 613	0 a 1
T62	Quantifier_or_Qualifier 550 560	Al menos 1
R20	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T62	
T63	CONC 654 658	ECOG
#50	AnnotatorNotes T63	C1520224; ECOG performance status; Intellectual Product
T64	CONC 618 652	Eastern Cooperative Oncology Group
#51	AnnotatorNotes T64	C1520224; ECOG performance status; Intellectual Product
R21	Has_Result_or_Value Arg1:T64 Arg2:T61	
R22	Has_Result_or_Value Arg1:T63 Arg2:T61	
R24	Location_of Arg1:T15 Arg2:T14	
R25	Location_of Arg1:T16 Arg2:T14	
R26	Location_of Arg1:T33 Arg2:T32	
R27	Experiences Arg1:T41 Arg2:T14	
R28	Experiences Arg1:T41 Arg2:T32	
T65	Observation 795 813	foco de enfermedad
#52	AnnotatorNotes T65	C0449422; Source of disease; Finding
T66	Quantifier_or_Qualifier 789 794	único
R29	Has_Quantifier_or_Qualifier Arg1:T65 Arg2:T66	
R30	Experiences Arg1:T41 Arg2:T17	
R31	Location_of Arg1:T33 Arg2:T65	
R32	Location_of Arg1:T16 Arg2:T65	
R33	Location_of Arg1:T15 Arg2:T65	
R34	Location_of Arg1:T15 Arg2:T17	
R35	Location_of Arg1:T16 Arg2:T17	
R36	Location_of Arg1:T33 Arg2:T17	
T67	Quantifier_or_Qualifier 814 820	activa
#53	AnnotatorNotes T67	C0679217; Active State; Idea or Concept
R37	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T67	
R38	Experiences Arg1:T53 Arg2:T18	
R39	Location_of Arg1:T34 Arg2:T18	
T68	Quantifier_or_Qualifier 875 886	controladas
R40	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T68	
T69	Observation 887 908	podrán ser reclutados
#54	AnnotatorNotes T69	C1302261; Patient eligible for clinical trial; Finding (?)
R42	Overlap Arg1:T18 Arg2:T69	
R44	Speculation Arg1:T42 Arg2:T19	
R45	Experiences Arg1:T50 Arg2:T19	
T70	Quantifier_or_Qualifier 954 960	activa
#55	AnnotatorNotes T70	C0679217; Active State; Idea or Concept
R46	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T70	
R47	Experiences Arg1:T51 Arg2:T20	
R48	Experiences Arg1:T51 Arg2:T21	
R49	Used_for Arg1:T22 Arg2:T21	
R50	Has_Dose_or_Strength Arg1:T22 Arg2:T43	
R51	Has_Dose_or_Strength Arg1:T23 Arg2:T43	
T71	CONC 1081 1107	equivalentes de prednisona
R52	Experiences Arg1:T51 Arg2:T24	
R53	Overlap Arg1:T24 Arg2:T44	
R54	Overlap Arg1:T22 Arg2:T44	
R55	After Arg1:T24 Arg2:T35	
R56	After Arg1:T21 Arg2:T35	
R57	Experiences Arg1:T51 Arg2:T35	
R58	Experiences Arg1:T52 Arg2:T36	
T72	Result_or_Value 1282 1291	positivas
#56	AnnotatorNotes T72	C1446409; Positive; Finding
R59	Has_Result_or_Value Arg1:T36 Arg2:T72	
R61	Experiences Arg1:T52 Arg2:T37	
R62	Experiences Arg1:T52 Arg2:T38	
R63	Experiences Arg1:T52 Arg2:T25	
R64	Experiences Arg1:T52 Arg2:T26	
R68	After Arg1:T27 Arg2:T48	
R69	After Arg1:T27 Arg2:T49	
R70	Has_Dose_or_Strength Arg1:T28 Arg2:T49	
T73	CONC 1535 1555	inicio de la terapia
R71	After Arg1:T27 Arg2:T73	
#57	AnnotatorNotes T35	C3469597; Administration of medication; Therapeutic or Preventive Procedure
R17	Causes Arg1:T37 Arg2:T72	
R18	Causes Arg1:T38 Arg2:T72	
R19	Causes Arg1:T25 Arg2:T72	
R23	Causes Arg1:T26 Arg2:T72	
#58	AnnotatorNotes T66	C0205171; Singular; Quantitative Concept
#59	AnnotatorNotes R70	(?)
#60	AnnotatorNotes T49	C1762893; Date last dose; Temporal Concept
#61	AnnotatorNotes T21	C4053960; Systemic Corticosteroid Therapy; Therapeutic or Preventive Procedure
T74	Route 1041 1050	sistémico
#62	AnnotatorNotes T74	C0205373; Systemic; Functional Concept
R41	Has_Route_or_Mode Arg1:T22 Arg2:T74	
#63	AnnotatorNotes T14	C0751620; Central Nervous System Neoplasms, Primary; Neoplastic Process
A9	Experiencer T41 Patient
A10	Experiencer T53 Patient
A11	Experiencer T50 Patient
A12	Experiencer T51 Patient
A13	Experiencer T52 Patient
A14	Assertion T48 Hypothetical
A15	Experiencer T40 Patient
